Non-inferiority trials: why oncologists must remain wary

Mauricio Burotto; Vinay Prasad; Tito Fojo

doi:10.1016/S1470-2045(15)70129-4

Non-inferiority trials: why oncologists must remain wary

Mauricio Burotto, Vinay Prasad, Tito Fojo

Knight Cancer Institute

Research output: Contribution to journal › Comment/debate › peer-review

17 Scopus citations

Original language	English (US)
Pages (from-to)	364-366
Number of pages	3
Journal	The Lancet Oncology
Volume	16
Issue number	4
DOIs	https://doi.org/10.1016/S1470-2045(15)70129-4
State	Published - 2015

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(15)70129-4

Cite this

@article{a966d5252636431eb85937f6c24a4fbe,

title = "Non-inferiority trials: why oncologists must remain wary",

author = "Mauricio Burotto and Vinay Prasad and Tito Fojo",

year = "2015",

doi = "10.1016/S1470-2045(15)70129-4",

language = "English (US)",

volume = "16",

pages = "364--366",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "4",

}

TY - JOUR

T1 - Non-inferiority trials

T2 - why oncologists must remain wary

AU - Burotto, Mauricio

AU - Prasad, Vinay

AU - Fojo, Tito

PY - 2015

Y1 - 2015

UR - http://www.scopus.com/inward/record.url?scp=84933523935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933523935&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(15)70129-4

DO - 10.1016/S1470-2045(15)70129-4

M3 - Comment/debate

C2 - 25846084

AN - SCOPUS:84933523935

SN - 1470-2045

VL - 16

SP - 364

EP - 366

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 4

ER -

Non-inferiority trials: why oncologists must remain wary

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this